{"organizations": [], "uuid": "ecd351ae32b6ab511b2fe3597708ad89d935eefc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-tetraphase-pharmaceuticals-announc/brief-tetraphase-pharmaceuticals-announces-submission-of-nda-to-fda-for-eravacycline-to-treat-intra-abdominal-infections-idUSASB0BZI9", "country": "US", "domain_rank": 408, "title": "BRIEF-Tetraphase Pharmaceuticals Announces Submission Of NDA To FDA For Eravacycline To Treat Intra-Abdominal Infections", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-02T23:39:00.000+02:00", "replies_count": 0, "uuid": "ecd351ae32b6ab511b2fe3597708ad89d935eefc"}, "author": "", "url": "https://www.reuters.com/article/brief-tetraphase-pharmaceuticals-announc/brief-tetraphase-pharmaceuticals-announces-submission-of-nda-to-fda-for-eravacycline-to-treat-intra-abdominal-infections-idUSASB0BZI9", "ord_in_thread": 0, "title": "BRIEF-Tetraphase Pharmaceuticals Announces Submission Of NDA To FDA For Eravacycline To Treat Intra-Abdominal Infections", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "nda", "sentiment": "negative"}, {"name": "eravacycline to treat intra-abdominal infections reuters", "sentiment": "none"}, {"name": "tetraphase pharmaceuticals inc", "sentiment": "none"}, {"name": "ciai", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 2, 2018 / 9:39 PM / Updated 22 minutes ago BRIEF-Tetraphase Pharmaceuticals Announces Submission Of NDA To FDA For Eravacycline To Treat Intra-Abdominal Infections Reuters Staff 1 Min Read \nJan 2 (Reuters) - Tetraphase Pharmaceuticals Inc: \n* TETRAPHASE PHARMACEUTICALS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION TO FDA FOR ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI) \n* TETRAPHASE PHARMACEUTICALS INC - NDA SUBMISSION INCLUDES DATA FROM IGNITE1 AND IGNITE 4 PHASE 3 CLINICAL TRIALS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-02T23:39:00.000+02:00", "crawled": "2018-01-03T00:06:10.055+02:00", "highlightTitle": ""}